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Clinical trials of new antiepileptic drugs (AEDs) include regulatory studies aimed at demonstrating efficacy and reasonable safety,
post-marketing open-open label studies and longer term outcome studies. Regulatory trials involve a carefully selected population
of patients and are conducted under rigorously standardised conditions. Data from such studies cannot often be translated into
clinical practice. Pragmatic post-marketing studies using flexible dosing schedules allow clinicians to better judge the utility
of the new drug in a wider population of patients with epilepsy and decide the most appropriate dosing schedules. This paper
discusses some of the issues surrounding the measurement of efficacy of new AEDs in both pre- and post-marketing phases of
their development.
All of the newer AEDs are initially used in patients with refractory partial seizures as adjunctive treatment. These trials are
generally parallel-group studies although cross-over designs have been employed. The use of placebo-control is uncontroversial
in this type of study. Efficacy endpoints are generally manipulations of seizure frequency on study drug compared to control.
Global outcome measures and health related quality of life scores can also be used to measure efficacy.
As the standard AEDs are associated with a high rate of seizure remission in patients who receive them as monotherapy,
demonstration of superior efficacy of a new agent in a comparative trial will require large numbers of patients in a design that
takes into account the natural history of treated epilepsy. Comparing investigational agents to a standard AED in an ‘active-control’
study with demonstration of equivalent efficacy would seem to be an acceptable way of assessing efficacy of new AEDs in this
population. Some regulators, however, do not accept equivalence as proof of efficacy and insist on demonstration of superiority
compared to a control. The use of placebo alone in the control group is ethically dubious. Several innovative study designs have,
therefore, been used to satisfy regulatory requirements, while maintaining patient safety including withdrawal to monotherapy
using high versus low dose comparators.
Observational outcome studies provide the best opportunity of exploring the long-term utility of individual AEDs. Such
studies largely follow standard clinical practice and need considerable time and resources. They can, however, yield valuable
information about the effectiveness of AEDs in everyday clinical practice. Data from regulatory trials should be complemented
by postmarketing studies and longer term studies of outcome to help clinicians decide the best way of utilising new AEDs and
establishing their role in the therapeutic armamentarium.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Key words: antiepileptic drugs; monotherapy; epilepsies; clinical trials; effectiveness.
INTRODUCTION
The epilepsies are a group of heterogenous, multi-
faceted disorders that have physical, psychological
and social implications1. Nine new chemical entities
have been licensed world wide for the prevention of
seizures since the late 1980s2, 3. Nevertheless, only
60–65% of patients achieve remission with currently
available antiepileptic drugs (AEDs)4. There is clearly
a need for more new AEDs with novel mechanisms of
action5. Trials conducted to assess AEDs vary in their
design, methodology and end points depending on
who wants the information from them. Regulatory au-
thorities look for evidence of efficacy and safety, while
patients and doctors seek data on longer term clinical
utility and tolerability. The pharmaceutical companies
hope to meet the requirements of all parties. Most tri-
als aimed at demonstrating efficacy to meet regulatory
demands do not provide clinicians with the informa-
tion necessary to make treatment decisions6.
The setting for regulatory clinical trials is necessar-
ily artificial, the findings from which might not be
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reproducible in ‘real life’. Nevertheless, stringent pa-
tient selection based on strict protocols and exclusion
criteria are necessary to safeguard patients in these
trials and to provide unequivocal evidence of efficacy
for regulatory authorities7. Once efficacy in control-
ling seizures and reasonable safety have been demon-
strated, a license is obtained, initially as adjunctive
treatment and then as monotherapy, and clinicians
can start to gain experience with the drug and decide
its place in the therapeutic armamentarium8. Indica-
tions, titration schedules and recommended doses can
change and new adverse effects come to light in the
post-marketing period, which may have important im-
plications for the drug’s therapeutic usefulness. To ad-
equately evaluate benefits and risks of treatment for
chronic diseases, systematic reviews should consider
data from observational studies in addition to ran-
domised controlled trials9.
Observational studies can be useful adjuncts to ran-
domised, controlled trials to see whether the demon-
strated efficacy translates into effective treatment in
routine clinical practice10. This discussion paper will
touch on some of pre- and post-licensing efficacy is-
sues that need to be addressed before the value and
usage of a drug can be determined with any degree of
certainty. Details of the methodology relative to ma-
jor efficacy studies for the nine newer AEDs licensed
since 1989 are provided in Appendices A–I.
REGULATORY ISSUES
While regulatory authorities require proof of efficacy
and safety before a license can be granted, there are
differences in what is acceptable in different parts of
the world. The requirements for licensing an AED
as add-on in patients with refractory epilepsy are
largely non-controversial. Placebo-controlled, add-on
studies usually include a range of randomised doses
for the new AED. The aim is to show a clinically
useful dose–response relationship, ideally including
a non-effective dose, which will help identify the
effective dosage range.
When a monotherapy claim for newly diagnosed
epilepsy is requested, the Food and Drug Admin-
istration (FDA) in the United States usually insists
on two randomised double-blind trials showing ev-
idence of superiority of test drug over control as
proof of efficacy11. As many patients with newly di-
agnosed epilepsy will have their seizures controlled
with the first AED chosen4, often at modest or mod-
erate dosage12, a dose–response relationship can be
difficult to identify in this population13, 14.
The European Agency for Evaluation of Medicinal
Products (EMEA) recommends trials using estab-
lished AEDs as controls (active-control). Demonstra-
tion of ‘no difference’ between the new drug and
established treatment can be accepted as evidence of
efficacy. Although no placebo-controlled trials have
been carried out using the traditional AEDs, sufficient
historical evidence exists to support their efficacy15.
Active-control trials can, therefore be considered
valid if they reproduce the setting in which the com-
parator has been shown to be effective and for which
it has been licensed by the regulatory authority. One
advantage of active-control studies is that they al-
low the new agent to be tested as monotherapy for
the population of patients in whom it will later be
licensed. The FDA takes the view that ‘equivalence’
between the test drug and active-control could be sim-
ply due to lack of efficacy of both or because the trial
lacked sufficient sensitivity to differentiate between
them16. A number of strategies have been developed
to overcome this dilemma, including high dose ver-
sus low dose or ‘pseudoplacebo’ in withdrawal to
monotherapy designs.
ADJUNCTIVE TRIALS
All new AEDs are initially studied as adjunctive
treatment in patients who continue to have seizures
despite treatment with one or more AEDs. The use of
placebo in this setting is not considered unethical as
patients are already on treatment with conventional
drugs and are protected from status epilepticus by
their baseline medication. They are required to have a
defined number of seizures per unit time (e.g. four per
month) to be eligible for inclusion in a regulatory trial.
In the pre-treatment phase, existing therapy remains
stable and baseline seizure frequency is recorded usu-
ally over 8 weeks. Modern studies tend to follow a
parallel-group design. Cross-over studies have largely
gone ‘out of fashion’ because they are regarded as
methodologically less sound. Patients with partial
seizures with or without secondary generalisation are
recruited initially, since there still is substantial need
for effective treatment in this patient population17, 18.
Similar studies in the generalised epilepsies are
sometimes undertaken later although these are often
slow to recruit19. Efficacy against typical absences or
myoclonic jerks can be difficult to demonstrate.
Cross-over studies
This design involves patients receiving the drug and
placebo randomly in two separate treatment phases
separated by a washout period. Vigabatrin20 and
lamotrigine21 underwent European regulatory pro-
grammes based on randomised, placebo-controlled,
cross-over studies. This design allows the effects of
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drug and placebo to be studied within subjects and
can be particularly useful early in the development
programme22. There is a fundamental requirement
for seizure numbers to remain stable and predictable.
Only if seizure frequency returns to baseline when the
first treatment is stopped can the second be evaluated
under identical conditions. This can be a problem as
many patients tend to be recruited during a period of
exacerbation of their seizures which may remit over
time irrespective of therapy. Furthermore, if there has
been a clear beneficial effect during the first period
of treatment, there are ethical concerns about switch-
ing patients and consent for the second period might
not be forthcoming. Carry over effects can also in-
fluence results from the second period. In addition,
if the response to or toxicity with the test drug is
clearly different from that of placebo, blinding can
be difficult to maintain. For these reasons, regulatory
authorities are unlikely to accept cross-over trials as
primary proof of efficacy. However, useful informa-
tion on dose-ranging, pharmacokinetic interactions,
and side-effect profiling can be obtained using this
design23.
Parallel-group studies
This is regarded as the design of choice for the regu-
latory assessment of efficacy of new AEDs as adjunc-
tive therapy in difficult-to-control epilepsy. Patients
are randomised to receive one of several doses of drug
or matched placebo. Groups are compared for mea-
sures of efficacy and tolerability. This design has the
advantage that it is suitable for all stages of drug de-
velopment and a range of dose levels can be included
in the same study. The necessity for the seizure dis-
order to be stable is not vital in this design because
the comparison is between rather than within sub-
jects. Dose–response studies need to be carried out
with compounds seeking approval as adjunctive ther-
apy and demonstration of a clear-cut dose–response
relationship reassures all concerned that efficacy has
been demonstrated.
Results from these trials can be complicated by po-
tential pharmacokinetic and pharmacodynamic drug
interactions. Some limitations may be placed on the
number and types of baseline AEDs to help minimise
these problems, but they cannot be wholly eliminated.
It can be argued, indeed, that such studies assess the
efficacy and tolerability of AED combinations rather
than the drug under study. Giving lamotrigine to pa-
tients already taking sodium valproate will produce
a better response than those established on carba-
mazepine or phenytoin24. Indeed, synergism between
sodium valproate and lamotrigine has been confirmed
in an open, response-conditional, cross-over design
employing concentration measurement25. The combi-
nation of carbamazepine and lamotrigine, on the other
hand, is more likely to produce neurotoxic side-effects
due to an adverse pharmacodynamic interaction be-
tween the drugs24, 26. Combination effects may also
explain the substantial efficacy of the GABA-ergic
AEDs, vigabatrin and tiagabine, as add-on therapy in
refractory epilepsy27, 28, which was less impressive
when the drugs were used as monotherapy in newly
diagnosed localisation-related epilepsy29, 30.
MONOTHERAPY TRIALS
Evidence of efficacy from add-on studies has to be
available before such studies can be contemplated.
Most patients with untreated epilepsy can expect to
have their seizures controlled with one AED4. The
use of placebo-control in patients with newly diag-
nosed epilepsy can be regarded, therefore, as ethi-
cally dubious31. For regulatory purposes, the FDA
accepts only evidence of superiority over control as
proof of efficacy. There are difficulties in designing
clinically relevant monotherapy trials that meet their
requirements. Randomising patients to placebo alone
could be interpreted as being at odds with the Dec-
laration of Helsinki which stated that, “In any medi-
cal study all patients—including those in the control
group, if any—should be assured of the best proven
diagnostic and therapeutic method”. A revised ver-
sion, issued in October 2000, included a new section
(section 29) which stated “The benefits, risks, bur-
dens and effectiveness of a new method should be
tested against the best current prophylactic, diagnos-
tic and therapeutic methods”32. If interpreted literally,
this would appear to rule out placebo-controlled trials,
whenever licensed therapeutic options already exist.
However, judicious use of placebo is sometimes es-
sential to establish the efficacy of new treatments33.
A further ‘clarification’ of this section issued in Oc-
tober 2001 stated that placebo-controlled trials may
be justifiable even when effective treatments are avail-
able if there are compelling and scientifically sound
methodological reasons for their use with the caveat
that patients subjected to placebo treatment are as-
sured of no serious or long-lasting harm. In the con-
text of epilepsy, this could be interpreted to mean that
the use of placebo alone is justified only when gen-
uine doubt exists as to the effectiveness of the treat-
ment being evaluated (e.g. following first unprovoked
seizure), or when the risks from further seizures are
low (e.g. absence seizures).
In an attempt to avoid the ethical problems of us-
ing placebo controls, low doses of the study drug or
suboptimal doses of a standard AED have been used
as a ‘pseudoplacebo’. The rationale for this has been
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that while a low dose will protect against catastrophic
seizures, it will have little effect on the overall number
of partial seizures34. There is, however, no evidence to
support this. In addition, it can be argued that the using
a drug at a dose intended to be ineffective is equiva-
lent to using a placebo. A number of innovative study
designs have been used to satisfy regulatory require-
ments while maintaining patient safety. These ‘thera-
peutic failure’ paradigms require the demonstration of
worse seizure control in the low dose compared to the
high dose group35. Even with tightly defined exit cri-
teria, ethical concerns remain with such approaches36.
Pre-surgical withdrawal
These studies are carried out in patients who have
had their AEDs discontinued as part of seizure lo-
calisation investigations prior to possible epilepsy
surgery. Patients are randomised to the study drug or
placebo-control and are monitored until they meet
pre-defined exit criteria. These can include a specified
number of seizures, worsening of seizure severity, or
completion of a period on treatment. Primary efficacy
variables are usually time to exit and the percentage
of patients completing the study. This design can be
used as ‘proof of concept’ for AED efficacy.
Such protocols tend to last short periods (hours
to days) and yield little clinically relevant informa-
tion. Drugs that exhibit delay in onset of full clinical
effect (e.g. sodium valproate) and those that show
tolerance (e.g. benzodiazepines) may not be suitable
for this design. Once the patient has had sufficient
number of seizures for the purpose of localisation and
video-monitoring has been discontinued, any further
episodes will be for the benefit of the study alone.
Modifications have been suggested to address such
remaining ethical issues37, 38.
Conversion to monotherapy
Patients with difficult-to-control epilepsy taking
AEDs are randomised to receive active drug or con-
trol. The original AEDs, usually one or two, are then
tapered off and patients maintained, if possible, on
the new monotherapy. The use of placebo would be
unacceptable in this population of patients and, there-
fore, suboptimal comparators (low dose of study drug
or of another AED) are used instead as controls. The
aim is to show that significantly more patients can be
maintained on monotherapy with the study drug at
high than on low dosage39. Exit criteria are defined
in terms of number and severity of seizures. This
follows clinical practice to a limited extent inasmuch
as it seeks to withdraw concomitant AEDs in patients
whose seizures are controlled when a new drug is
added40. However, target doses of the study drug are
usually fixed and the substitution protocol is often
rigid. Maintaining responders on monotherapy for an
extended period can yield valuable safety informa-
tion. These studies have a variable track record in
demonstrating efficacy of new AEDs as monotherapy
and ethical concerns surrounding the use of pseudo-
placebos remain. A recent proposal under discussion
is to drop the low dose comparator and compare the
withdrawal rate on high doses of new AEDs with
‘historical’ controls from previous trials.
Active-control
These trials are carried out in drug-naı¨ve patients with
newly diagnosed epilepsy. The study drug is compared
to standard doses of an established AED using a ran-
domised, double-blind design. This approach has the
advantage of comparing the new drug head-to-head
with standard treatment without the confounding ef-
fect of comedication withdrawal. As the majority of
newly diagnosed patients experience seizure remis-
sion with the first AED chosen4, often at low or mod-
erate dosage12, demonstrating superior efficacy will
require large numbers of patients followed-up over
long periods of time using a flexible dosage design.
Demonstrating ‘equivalence’ is usually accepted as
evidence of efficacy by European regulators. These
active-control studies aim to show that the study drug
is not inferior to the standard AED which has histor-
ically been shown to be effective for the seizure type
under study. Although the scientific validity of this
design has been questioned41, it would seem to be a
logical method of assessing the effectiveness of AEDs
drugs as potential first choice treatment in newly di-
agnosed epilepsy. Furthermore, there are fewer ethi-
cal implications in these types of studies, which are
largely acceptable to patients and doctors42.
Methodological integrity is important in equiva-
lence studies. It is not acceptable to carry out the
trial as a comparative study and interpret the lack of
statistically significant difference as definite proof of
equivalence43. The null hypothesis is that there exists
a difference between the treatments (delta—the confi-
dence interval around equivalence). If this is rejected,
the alternative hypothesis, i.e. that the treatments
are equivalent, is accepted. In demonstrating clinical
equivalence, the limits of difference with respect to
important outcomes such as seizure remission should
be decided at the design stage. For AEDs, this is usu-
ally taken as 10%. If the study drug is shown to be no
more than 10% different from the active comparator,
it can be assumed that it is at worst 10% inferior to
standard treatment44. Sample sizes need to be large,
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although optimal numbers can be guaranteed by using
a sequential design45. Intention to treat analysis is no
longer conservative and per protocol analysis should
also be presented46. European regulators have ruled
that the delta should be set as far as possible from the
placebo zone and that the natural history of the dis-
order should be taken into account when deciding it.
Active-control trials have been criticised in the past
over choice of doses and titration schedules. If the
established comparator is started at a low dose and
titrated to moderate dosage in accordance with nor-
mal clinical practice, this may be interpreted as in-
troducing bias in favour of the efficacy of the trial
drug. If, however, more aggressive regimes are em-
ployed, the tolerability of the new AED can appear
exaggerated.
CLINICAL END POINTS
All new AEDs are initially evaluated as add-on treat-
ment for patients with seizure disorders not controlled
with one or more standard agents. Once adjunctive
studies have proven the efficacy of the trial drug, a
monotherapy programme can be initiated. Complete
seizure control is not regarded as a realistic end point
for the majority of patients with refractory epilepsy.
Standard end points are manipulations in the number
of seizures between the baseline and treatment periods.
Seizures can be difficult to count especially if they oc-
cur in clusters47. Distinguishing between the various
types can also be problematic. The non-parametric na-
ture of the data can make analysis challenging. While
seizure frequency can only be decreased by 100%,
it can be increased infinitely. Several non-parametric
paradigms have been devised to address this problem.
The response ratio, for example, allows for normalisa-
tion of the percent change in seizure frequency which
always falls in the range of −100 to +10048, 49.
Changes in seizure frequency
Seizures are counted over a defined period of time,
e.g. 1 or 3 months, and the number occurring in pa-
tients receiving the test drug is compared with that
in controls. When analysed as a continuous variable,
seizure frequency is the most sensitive measure of
efficacy and should be used whenever possible50.
However, skewed distribution can make data handling
difficult using standard statistical methods without
transformation. Percentage reduction in seizure fre-
quency between baseline and treatment periods, al-
though superficially an attractive alternative, is prone
to be unduly influenced by outliers. Analysis using
seizure frequencies during baseline and treatment pe-
riods (transformed if necessary) as covariates can be
regarded as a better option.
Proportion of responders
When patients exhibit seizures within a wide range
suggesting non-normal or multimodal distribution,
frequency has to be assessed as a dichotomous (bi-
nary) variable. Percentage of subjects with 50% (or
some other arbitrary figure) reduction in seizure
frequency can be compared among groups. One ad-
vantage of such an analysis is that it has been used
frequently and, therefore, allows comparisons with
previous studies using different AEDs51. A minimum
of 50% reduction in seizure frequency is the dichoto-
mous cut off point usually quoted in clinical trials.
This is arbitrary, however, and may miss important
differences between treatments. Categorisation of
seizure frequencies can be used instead of a single
cut off point; e.g. 0–19%, 20–39%, 40–59%, >75%
reductions, etc.50. Seizure freedom is not generally
quoted as a primary outcome measure, because of
the refractoriness of epilepsy in this population and
the use of predetermined titration schedules and fixed
doses of AEDs. Nevertheless, this observation is
probably underused.
Seizure-free days
In studying the effect of levetiracetam in patients with
refractory epilepsy, French et al.52 reported an analy-
sis of seizure-free days to determine efficacy. This was
carried out by evaluation of seizure diaries. In con-
trast to standard analyses, where the total number of
seizures in a set period of time are counted, this ap-
proach looks at each day individually to see whether
or not a seizure has occurred. Such day by day evalu-
ation can allow seizure patterns and response timings
to be addressed. One aim of this approach is to ob-
tain a flavour of the time-to-effect with the test drug
compared to placebo-control.
Time to nth seizure
Time to first seizure is a commonly quoted end point
for monotherapy trials especially in pre-surgical with-
drawal studies. Pledger and Sahlroot53 have shown
that this type of analysis can be applied equally to
adjunctive trials with fixed treatment periods. This
outcome measure has also been used in active-control
monotherapy comparisons29, 54. One potential pit-
fall in newly diagnosed epilepsy is excluding the
possibility that any difference between the new and
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established agent in time to first seizure was a conse-
quence of differences in titration schedules or main-
tenance dosing. These values are usually well known
for the older agents, but not necessarily for the new
AED at the time of the study. Time to second, third,
fourth seizure, etc. can be more useful endpoints54.
Seizure severity
Even if a treatment does not abolish seizures com-
pletely, reduction in severity can be often achieved.
Examples are fewer secondary generalised seizures
in relation to numbers of complex partial seizures
or fewer complex partial compared to simple partial
events with awareness retained. Shortening of the
post-ictal recovery period could allow patients to re-
turn to normal activity sooner following a seizure.
Three scales are available to measure the severity
of seizures. These are the Veterans Administration
Seizure Severity and Frequency Rating Scale55, the
Liverpool Seizure Severity Scale56 and the National
Hospital Seizure Severity Scale (formerly known as
the Chalfont Seizure Severity Scale)57. Each has its
strengths and weaknesses58, 59. New instruments ad-
dressing their shortcomings are in development60.
Seizure severity scales need to be reliable, valid and
sensitive. Although the psychometric properties of
these scales are well established, there is little ev-
idence to support their clinical utility. Until more
data become available, seizure severity scales cannot
be recommended as standard outcome measures in
evaluating the efficacy of AEDs61.
Electroencephalography (EEG)
Once a drug has demonstrated anti-seizure activity in
animal models, the decision whether to proceed with
clinical development is a commercial one. Pivotal
studies in man require prolonged administration over
months in many patients with several types of seizures.
This programme takes years to complete and de-
mands considerable resources. Preliminary evidence
of efficacy is valuable to help with decision-making.
Surrogate endpoints, such as electroencephalographic
changes, can provide indications of potential efficacy.
Generally, epileptiform discharges do not correlate
with the severity of the seizure disorder62. Neverthe-
less, under standard recording conditions meaningful
effects of AEDs may be demonstrable in patients with
suitably high and stable rates of epileptiform EEG
discharges63. Acute experiments require a rapidly
effective formulation of the drug (preferably intra-
venous) tested under rigorously standardised condi-
tions. The drug is usually compared to both placebo
and an active-control (e.g. diazepam) employing a
cross-over design. The primary outcome measure is
the spike count per minute or the percentage of the
total recording occupied by discharges. Subacute ex-
periments can be carried out over longer time periods
(e.g. 24–48 hours) using telemetry or ambulatory EEG
monitoring. These reduce problems with spontaneous
variation in the rate of epileptiform discharges. This
can also be achieved by measuring evoked responses
such as the photoparoxysmal response in photosen-
sitive subjects. Reduction in photosensitivity can be
demonstrated after a single dose of various AEDs at
clinically relevant plasma concentrations64. However,
less than 1% of patients with epilepsy are suitable for
such studies and the scarcity of subjects is a major
limitation in recruitment65.
Surrogate measures of efficacy using EEG tech-
niques have not been widely used in the development
of new AEDs, with the possible exception of lam-
otrigine, which underwent assessment for interictal
spikes66 and photosensitivity67. While suppression
of epileptiform discharges may encourage further de-
velopment of the drug, lack of such efficacy should
not be grounds for termination of development. The
decisive test of efficacy for any AED is whether it pre-
vents seizures and the earlier that this is demonstrated
the better. Attempts to use intensive EEG monitoring
to support efficacy claims in absence epilepsy and
severe epilepsy syndromes in infants have been tried
with variable success68–72.
EFFECTIVENESS
The effectiveness of an AED is a function of its
efficacy and tolerability. The single most relevant
outcome measure that reflect both these factors is
the life table that expresses the retention of patients
on a particular treatment over a length of time73. A
similar table including just seizure-free patients has
the potential to refine further this outcome measure.
Patients are withdrawn from treatment when a prede-
termined combination of insufficient seizure control
and/or poor tolerability is reached. This approach
conforms to everyday practice and can provide useful
clinical information.
Regulatory authorities seek, over and above every-
thing else, evidence of efficacy. Retention time alone
does not provide this and, hence, life table analysis
alone is less suitable for regulatory trials. A drug that is
only modestly efficacious but has excellent tolerability
might fare better than one that is more efficacious but
is more prone to produce side effects74. In addition, if
patients are withdrawn from the trial for reasons other
than those related to efficacy and tolerability (e.g. in-
appropriate titration schedule, poor compliance, lost
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to follow up, etc.) the results can be misleading. In
such circumstances, the analysis can be done exclud-
ing these data (evaluable population) in addition to in-
cluding all randomised patients (intention to treat)45.
Measures of efficacy
The main objective of treatment with antiepileptic
medication is control of seizures with acceptable toler-
ability. Therefore, an essential outcome measure is the
proportion of patients achieving a predefined period
of seizure freedom73. Depending on the syndrome and
the patient population under study, remission may or
may not be a realistic goal. As the majority of newly
diagnosed adult patients with epilepsy can expect to
have their seizures completely controlled, seizure free-
dom from initiation of treatment or after titration is a
sensitive end-point for this population. This would not
be the case if the study population were, for instance,
infants with Lennox-Gastaut Syndrome.
The proportion of patients with complete control
of seizures can be measured at 1, 2 or 3 years from
treatment initiation. This provides the most clini-
cally meaningful data for predicting the long-term
efficacy of an AED50. Time to achieving 1-year of
seizure-freedom (or some similar end point) focuses
directly on the main aim of treatment. It has the ad-
vantage that patients, who continue to have seizures
for a period after starting on treatment, can also be
included73. Both the above end points, while lending
themselves to statistical and intuitive analyses, can be
insensitive. They require complete control of seizures
as evidence of efficacy, and discount patients who
experience even a single seizure due, for instance,
to a lapse in compliance or an intercurrent gastroin-
testinal infection. Detecting differences in efficacy
among patients not fully controlled is possible using
seizure rates, i.e. number of seizures over a unit time.
This can also be used to compare two treatments. If
patients are lost to follow up, this approach becomes
less valuable. Although an ‘intention to treat’ analysis
addresses this issue, results can still be distorted.
Measures of adverse effects
While no important differences in efficacy have been
shown among AEDs in regulatory trials, differences
have been seen in tolerability75, 76, which is assessed
by the incidence, prevalence, severity and the impact
of side effects50. Adverse events include issues re-
lating to tolerability and safety. The most important
outcome measure is withdrawal of a drug because of
intolerable or life threatening side-effects. Surveil-
lance for organ toxicity is maintained by history,
physical examination and laboratory testing. Life
threatening idiosyncratic reactions, with the exception
of hypersensitivity rash, are extremely rare. Regula-
tory trials do not involve sufficient number patients to
uncover these events. Post-marketing surveillance is
more important in detecting these uncommon but po-
tentially serious problems. Major safety concerns with
felbamate and vigabatrin were identified in this phase.
Neurotoxic adverse effects such as sedation, dizzi-
ness and diplopia tend to resolve with a reduction in
dose. This may not be allowable in a fixed dose study
and so the patient may drop out and, therefore, not gain
efficacy from the drug30. These and other systemic
adverse effects, including gastrointestinal upsets, may
also abate with time. The development of tolerance
to initial neurotoxicity may allow higher doses to be
used at a later date. An end point that records only
the incidence of adverse effects will not make this dis-
tinction. Patient based scales have been developed to
measure the neurotoxic effects of AEDs77.
Historically, many clinical trials of AEDs have
used incidence reporting of adverse events after pas-
sive inquiry. This is now recognised as inadequate50.
Such studies have relied on spontaneous reporting of
adverse effects by patients. While having the advan-
tage of highlighting clinically relevant problems, this
method is associated with substantial variability in
sensitivity and detection. Spontaneous reporting tends
to underestimate side-effects, as patients may not
make the association between subtle problems and
AED therapy. Patients might also not recall transient
mild symptoms. Therefore, some form of standard-
isation in interview and examination has been rec-
ommended to supplement spontaneous reporting50.
Checklists should be used for recording adverse
events during randomised trials.
Why focus on adverse effects in a discussion paper
on efficacy? The reason is that efficacy and tolerability
cannot be sensibly separated. They combine to form
effectiveness. If a patient develops a rash or drops
out of a study due to neurotoxicity, data from this
individual will not contribute to the drug’s efficacy. A
major difference in tolerability can distort the clinical
or scientific relevance of efficacy end-points. Thus, in
a recent double-blind trial of carbamazepine versus
lamotrigine in the elderly, no differences in efficacy
could be demonstrated even though twice as many
patients taking lamotrigine remained seizure-free due
to its better tolerability and, therefore effectiveness78.
Dosage
Doses used in regulatory trials are frequently differ-
ent from those subsequently found to be effective
in routine clinical practice. Thus, gabapentin is now
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prescribed in higher amounts (up to 4800 mg daily)
than those doses originally studied (900–1800 mg
daily) and subsequently licensed (up to 2400 mg
daily)48, 49, 79–83. On the other hand, the titration
schedules (50 mg weekly) and maintenance doses
(200–800 mg daily) for topiramate in regulatory
studies were more robust than now recommended
producing high responder rates but at the expense of
numerous adverse events84–89. Prospective observa-
tional studies have shown that good outcomes can be
obtained in many patients with substantially lower
amounts of topiramate (50–200 mg daily) than those
used in regulatory trials90, 91. The recommended titra-
tion schedule now starts with 25 mg topiramate daily
with weekly or 2 weekly increments of 25–50 mg
daily. As the primary aim of a regulatory trial is to
demonstrate efficacy, the tendency will be to err on
the side of fast titration and higher dosing. Well de-
signed post-marketing studies can allow clinicians to
gauge the optimal titration schedules and effective
doses for less severely affected patients taking the
drug in everyday clinical practice.
Concentration measurement
Serum levels of AEDs can be used to augment the
daily dose in controlled clinical trials. Concentration-
defined trials were used in the unsuccessful devel-
opment of flunarizine92 and with lamotrigine93. The
basis for this approach is the empirical observation
that serum concentrations may correlate better with
clinical response than does dose. This could reduce
interpatient variability and make the trial statistically
more efficient35. Drug levels are monitored and con-
trolled in an effort to identify a concentration–effect
relationship. Such data were helpful in supporting
the license claim for zonisamide as add-on ther-
apy in the US94. A concentration–response trial
has also been carried out with sodium valproate as
monotherapy in partial epilepsy95. Many of the newer
AEDs, however, do not exhibit clinically relevant
concentration–effect–toxicity relationships81, 90, 96.
Quality of life
Health related quality of life (HRQOL) measure-
ments have been an area of increasing interest in
recent years97. Several generic instruments measur-
ing HRQOL can be used in patients with epilepsy61.
In addition, a number of scales specific to epilepsy
have been devised. The latter include the Liverpool
HRQOL battery98, Epilepsy Surgery Inventory99 and
QOL in Epilepsy (QOLIE) instruments100. These
attempt to quantify emotional, functional and psy-
chosocial well-being. They are heavily dependent
on seizure freedom, however, and are unlikely to be
independent outcome variables in clinical trials of
AEDs101.
OBSERVATIONAL OUTCOME STUDIES
Epilepsy is a chronic condition. Most patients take
AEDs for many years and many receive lifelong treat-
ment. Studies that follow patients up over prolonged
periods of years can provide an insight into the nat-
ural history of treated epilepsy. These data can help
identify patients who are likely to enter remission and
those who have a more progressive seizure disorder.
These studies require substantial resources and do not
usually attract the same level of commercial or grant
funding as regulatory or comparative trials. How-
ever, they can help identify the best way of utilising
new treatments. The modern AEDs are, not surpris-
ingly, more expensive than the older agents. A recent
cost–benefit assessment of lamotrigine has, for in-
stance, suggested that the costs associated with newer
AEDs might be unjustifiably high102. The assump-
tions in this study have been challenged103, but the
fact remains that significant proportion of health care
budgets for epilepsy is taken up by the newer AEDs.
There seems little doubt that they have helped patients
whose seizures might otherwise have remained un-
controlled. In addition, the use of individual drugs can
be of substantial value in specific epilepsy syndromes,
e.g. vigabatrin for infantile spasms104. It would,
therefore, make economic sense to invest in studies of
sufficient scope and magnitude that could help iden-
tify the optimal place and usage of AEDs in clinical
practice.
Methodology
The basic requirement for any long-term outcome
study is that it follows routine clinical practice as
closely as possible. Exclusion criteria should be
kept to a minimum. Patients with newly diagnosed
epilepsy differ from those with difficult-to-control
seizures in terms of expected outcomes, side-effect
profiles and quality of life issues. These groups
should be studied separately. Patient care should not
vary from normal except for closer follow up and
more objective assessment of efficacy and tolerabil-
ity. Rating systems should be used for documenting
seizures and side-effects, taking into account their
number and severity together with objective assess-
ments of behavioral and cognitive status. Individ-
ual seizure types or epilepsy syndromes should be
studied separately and rigorous standards applied to
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diagnosis and classification. Pre-defined protocols
should be followed in investigating and monitoring
patients. Sample sizes required to answer specific
questions should be calculated prior to commence-
ment, and anticipated losses due to non-drug re-
lated events should be taken into consideration. In
newly diagnosed epilepsy, the incentive to continue
treatment and attend follow up appointments may
not be as persuasive as in patients with refractory
seizures.
These studies can be observational where each
patient’s treatment is deliberately chosen or randomly
assigned. Dosing schedules should be flexible tailor-
ing therapy for the individual patient. This allows the
therapeutic potential of each AED to be maximised.
There is an unavoidable risk of selection bias and
differences in outcomes might not always be due to
differences in treatment. Adjustments for identifiable
variation in patient characteristics at the analysis stage
can mitigate this. Unsophisticated post-marketing
surveillance tends to cause more problems than it
solves and these studies are best undertaken for safety
than efficacy reasons105.
End points
In monotherapy studies in newly diagnosed epilepsy,
the majority of patients can be expected to enter re-
mission with appropriate therapy. Time to first seizure
can, therefore, be a relevant end point assuming ap-
propriate AED titration and dosing. The number of
patients who have not suffered a first seizure would
represent the number who have remained fully con-
trolled. In longer term studies of outcomes, the pro-
portion of patients remaining free of seizures after 1,
2 and 3 years of follow-up will provide a useful in-
dication of effectiveness. These measures, combined
with quality of life issues such as employment, driv-
ing, etc. reflect the real impact of AED treatment on
the lives of people with epilepsy.
As discussed above, the incidence, prevalence and
severity of adverse effects is an important determinant
in the success of AED treatment. Withdrawal of a drug
because of adverse effects is a definitive end point in
a clinical study. For patients with difficult-to-control
epilepsy, drug burden can significantly impair qual-
ity of life. In the VA co-operative study, a complex
approach was used to quantify the efficacy and toxi-
city of phenytoin, carbamazepine, phenobarbital and
primidone75. Seizure frequency and severity, neuro-
toxicity, systemic and behavioral toxicity, and reten-
tion time on treatment were the primary variables.
These were computed into a single composite score
which allowed relative effectiveness of each of the
four drugs to be compared55.
META-ANALYSES
In the absence of comparative studies, meta-analyses
of individual clinical trials can give clinicians an im-
pression of how these drugs might stack up in terms of
efficacy and side-effects. Meta-analyses of adjunctive
clinical trials showed no significant differences in effi-
cacy among the various new AEDs studied27, 51. These
analyses were based on odds ratios, and it has been
suggested that number-needed-to-treat might be better
suited to demonstrate differences in efficacy106. This
is the number of patients requiring treatment in order
to achieve a single occurrence of a specified outcome.
This measure has the advantage of being readily inter-
pretable by clinicians, although it does have some un-
desirable statistical properties107. In meta-analyses of
AED trials, it is not possible to compare newer AEDs
with traditional ones, as none of the older agents (with
the exception of sodium valproate) has been evaluated
as add-on treatment in a controlled clinical trial108.
Moreover, as these trials were restricted to adjunctive
treatment for partial onset seizures, few conclusions
can be drawn about the use of these drugs as monother-
apy or in the treatment of other seizure types.
CONCLUSIONS
The epilepsies are a range of multifaceted disorders
that can affect many aspects of a person’s life. No sin-
gle outcome measure can reflect their complex nature
and impact in the individual patient. The aim of drug
treatment is the prevention of seizures with no or toler-
able side-effects. While this is possible for the major-
ity of patients, there remains a significant proportion
in whom ongoing seizures and increasing drug burden
exact a heavy toll. Efficacy has to be the first consider-
ation in the development of any new AED. However,
trials aimed at demonstrating efficacy to meet regula-
tory requirements rarely produce data that are helpful
to doctors who treat people with epilepsy. The out-
come measures in these trials, while admirably suited
to demonstrating statistical differences, are of dubious
clinical relevance. The real test is how a new AED
stands up to scrutiny in clinical practice. Well de-
signed observational studies can help doctors decide
their value. The end points in these studies should in-
clude both global outcome measures, such as the life
table of retention on treatment, as well as specific mea-
sures of efficacy and tolerability. Analyses should ex-
plore effects in different seizures types and epilepsy
syndromes. Measures of subjective health status can
be used as secondary endpoints. A combination of
randomised and observational studies will help decide
the eventual place of a new AED in the therapeutic
armamentarium.
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Appendix A Clinical trials with felbamate.
Study Design Number of Duration Efficacy References
patients measures
Add-on studies
Leppik et al., 1991 Add-on 56 8 weeks Difference in mean
seizure frequency
1











Sachdeo et al., 1992 Add-on 44 112 days Number of patients
meeting exit criteria
3










Jensen, 1994 Add-on 76 Not stipulated Percentage change in
seizure frequency
5
Double-blind >50% seizure reduction
Placebo-controlled
Parallel-group

















Devinsky et al., 1995 Monotherapy 52 10 days Average daily seizure
frequency
9
Pre-surgical Time to fourth seizure
Double-blind
Placebo-controlled
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Study Design Number of Duration Efficacy References
patients measures
Avanzini et al., 1996 Add-on 351 2 months Seizure freedom 13
Open-label >50% seizure
reduction
Li et al., 1996 Open-label 111 4 months (mean) Seizure freedom 14








Canger et al., 1999 Add-on 36 10 months (mean) Seizure freedom rate 16
Open-label >50%/>75% seizure reduction
Cilio et al., 2001 Add-on 36 Not stipulated >50% seizure reduction 17
Open-label
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Study Design Number of Duration Efficacy References
patients measures
The US Gabapentin
Study Group No. 5,
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Trudeau et al., 1996 Monotherapy (de novo) 33 children
(absence seizures)



















Chadwick et al., 1998 Monotherapy (de novo) 218 24 weeks Retention time 12
Double-blind
Active-control (CBZ)
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patients efficacy











































Boas et al., 1996 Add-on 56 12 weeks Percentage reduction
in seizure frequency
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Beran et al., 1998 Add-on 26 20 weeks Percentage reduction
in seizure frequency
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Double-blind >50% seizure reduction
Placebo-controlled
Cross-over







428 R. Mohanraj & M. J. Brodie
Appendix C (Continued ).
Study Design Number of Duration Measure of References
patients efficacy













Brodie et al., 1995 Monotherapy (de novo) 260 48 weeks Seizure freedom 17










Brodie et al., 1999 Monotherapy (de novo) 150 (elderly) 24 weeks Time to first seizure 19
Randomised Seizure freedom
Double-blind Retention on treatment
Parallel-group
Active-control (CBZ)
Steiner et al., 1999 Monotherapy (de novo) 92 48 weeks Seizure freedom 20
Double-blind Proportion remaining
on treatment
Parallel-group Time to first seizure










Frank et al., 2000 Monotherapy (typical
absence seizures)











Reunanen et al., 1996 Monotherapy (de
novo)




Karlsborg et al., 1996 Monotherapy 343 Not stipulated Seizure freedom 25
Open-label
Active-control (CBZ)
Buchanan, 1996 Add-on 92 Not stipulated Seizure freedom 26
Open-label >50% seizure reduction
Farrell et al., 1997 Add-on 200 1–4 years Seizure freedom 27
Open-label Percentage reduction
in seizure frequency
Buoni et al., 1998 Add-on 56 Not stipulated Seizure freedom 28
Open-label >50% seizure reduction
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patients efficacy
Gericke et al., 1999 Add-on 63 1–3 years Percentage reduction
in seizure frequency
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Social and academic
performance












Mauri-Llerda et al., 2001 Add-on 41 Not stipulated Percentage reduction
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Open-label >50% seizure reduction
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Appendix E Clinical trials with oxcarbazepine.
Study Design Number of Duration Efficacy References
patients measures
Add-on studies














Reinikainen et al., 1987 Monotherapy
(substitution for PHT)















Christe et al., 1997 Monotherapy (de novo) 249 56 weeks Seizure-free rates 6










Schachter et al., 1999 Monotherapy 102 10 days Time to exit 8
Pre-surgical Proportion of patients
exiting




4. Betts, T., Waegemans, T. and Crawford, P. A multicentre,
double-blind, randomized, parallel group study to evaluate the
tolerability and efficacy of two oral doses of levetiracetam,
2000 mg daily and 4000 mg daily, without titration in patients
with refractory epilepsy. Seizure 2000; 9: 80–87.
5. Cramer, J. A., Arrigo, C., Van Hammee, G. et al. Effect of
levetiracetam on epilepsy-related quality of life. N132 Study
Group. Epilepsia 2000; 41: 868–874.
6. Boon, P., Chauvel, P., Pohlmann-Eden, B. et al. Dose–response
effect of levetiracetam 1000 and 2000 mg/day in partial
epilepsy. Epilepsy Research 2002; 48: 77–89.
7. Grant, R. and Shorvon, S. D. Efficacy and tolerability of 1000–
4000 mg per day of levetiracetam as add-on therapy in patients
with refractory epilepsy. Epilepsy Research 2000; 42: 89–95.
8. Glauser, T. A., Pellock, J. M., Shields, W. D. et al. Efficacy
and safety of levetiracetam in children with partial seizures:
an open-label trial. Epilepsia 2002; 43: 518–524.
432 R. Mohanraj & M. J. Brodie
Appendix E (Continued ).
Study Design Number of Duration Efficacy References
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Sachdeo et al., 1997 Monotherapy (conversion) 48 16 weeks Completion rate 12
Double-blind Time to exit
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Open-label studies
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Appendix I Clinical trials with zonisamide.
Study Design Number of patients Duration Efficacy measures References
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Open-label
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